Loading...
Please wait, while we are loading the content...
Similar Documents
CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target
| Content Provider | MDPI |
|---|---|
| Author | Malik, Shivani Westcott, Jill M. Brekken, Rolf A. Burrows, Francis J. |
| Copyright Year | 2021 |
| Description | Pancreatic ductal adenocarcinoma (PDAC) is a disease with limited therapeutic options and dismal long-term survival. The unique tumor environment of PDAC, consisting of desmoplastic stroma, immune suppressive cells, and activated fibroblasts, contributes to its resistance to therapy. Activated fibroblasts (cancer-associated fibroblasts and pancreatic stellate cells) secrete chemokines and growth factors that support PDAC growth, spread, chemoresistance, and immune evasion. In this review, we focus on one such chemokine, CXCL12, secreted by the cancer-associated fibroblasts and discuss its contribution to several of the classical hallmarks of PDAC and other tumors. We review the various therapeutic approaches in development to target CXCL12 signaling in PDAC. Finally, we propose an unconventional use of tipifarnib, a farnesyl transferase inhibitor, to inhibit CXCL12 production in PDAC. |
| Starting Page | 86 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers14010086 |
| Journal | Cancers |
| Issue Number | 1 |
| Volume Number | 14 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-12-24 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Pancreatic Cancer Tumor Microenvironment Cancer-associated Fibroblast Cxcl12 Cxcr4 |
| Content Type | Text |
| Resource Type | Article |
